|Acquired by||Abbott Labs|
|Partial Close, 5/2010 ||$12.9M|
|Series D, 10/2010 |
Piper Jaffray Private Capital Group
Bay City Capital
|Debt, 3/2012 ||$831k|
IDEV Technologies is an emerging growth medical device company focused on the development of products for endovascular and interventional applications. Currently, IDEV markets SUPERA, a novel self-expanding nitinol stent. Using a patented interwoven design, SUPERA offers improved flexibility, radial strength, and kink and crush resistance compared to other marketed stents. SUPERA is currently approved for use in the treatment of biliary strictures in the US. IDEV is currently enrolling patients in the SUPERB IDE trial to study SUPERA’s safety and efficacy when used in the superficial femoral artery (SFA).